Home Cart Sign in  
Chemical Structure| 3458-28-4 Chemical Structure| 3458-28-4

Structure of D-Mannose
CAS No.: 3458-28-4

Chemical Structure| 3458-28-4

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

D-Mannose, a carbohydrate, can participate in glycosylation of proteins and metabolism of the body.

Synonyms: Carubinose; NSC 26247; (+)-Mannose

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of D-Mannose

CAS No. :3458-28-4
Formula : C6H12O6
M.W : 180.16
SMILES Code : O=C[C@H]([C@H]([C@@H]([C@@H](CO)O)O)O)O
Synonyms :
Carubinose; NSC 26247; (+)-Mannose
MDL No. :MFCD00799233

Safety of D-Mannose

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
RAW264.7 cells 25 mM Inhibited osteoclast proliferation and fusion PMC9827691
Rat bone marrow monocytes (rBMMs) 25 mM 4 days Suppressed osteoclast proliferation and bone resorption capacity PMC9827691
Human macrophages derived from peripheral blood monocytes 11 mM 24 h Inhibited IL-1β production PMC7733482
RAW 264.7 murine macrophage cell line 11 mM 24 h Inhibited pro-inflammatory cytokine IL-1β production PMC7733482
Rat kidney epithelial NRK-52E cells 20 mM 2 h To investigate the inhibitory effect of D-Mannose on cisplatin-induced GSDME-dependent pyroptosis. Results showed that D-Mannose substantially suppressed cisplatin-induced pyroptotic morphology, GSDME cleavage, and LDH release. PMC10709431
Human normal intestinal FHs 74 Int cells 20 mM 2 h To investigate the inhibitory effect of D-Mannose on cisplatin-induced GSDME-dependent pyroptosis. Results showed that D-Mannose substantially suppressed cisplatin-induced pyroptotic morphology, GSDME cleavage, and LDH release. PMC10709431
Human breast cancer MDA-MB-468 cells 20 mM 2 h To investigate the inhibitory effect of D-Mannose on raptinal-induced GSDME-dependent pyroptosis. Results showed that in GSDME-overexpressing MDA-MB-468 cells, raptinal-induced pyroptosis was clearly inhibited by mannose. PMC10709431
Human lung adenocarcinoma PC-9 cells 20 mM 2 h To investigate the inhibitory effect of D-Mannose on raptinal-induced GSDME-dependent pyroptosis. Results showed that in GSDME-overexpressing PC-9 cells, raptinal-induced pyroptosis was clearly inhibited by mannose. PMC10709431
Melanoma A375 cells 20 mM 2 h To investigate the inhibitory effect of D-Mannose on CCCP/FeSO4-induced GSDME-dependent pyroptosis. Results showed that D-Mannose dramatically reversed CCCP/iron-induced pyroptosis, including pyroptotic morphology, GSDME cleavage, and lactate dehydrogenase (LDH) release. PMC10709431
peritoneal macrophages 20 mM 12 h To assess the effect of mannose on TNF-α production in macrophages. Results showed that mannose significantly suppressed LPS-induced TNF-α production, and this effect was achieved by reducing GAPDH binding to TNF-α mRNA. PMC9887054
colon organoids 10 mM 24 h To investigate the effect of mannose on inflammation-induced damage in colon organoids. Results showed that mannose significantly rescued the viability of organoids and reduced the expression of ERS markers. PMC9887054
intestinal epithelial cells (IECs) 10 mM 24 h To evaluate the effect of mannose on inflammation-induced endoplasmic reticulum stress (ERS). Results showed that mannose significantly reduced the expression of GRP78 and CHOP, indicating its ability to alleviate inflammation-induced ERS. PMC9887054
Mouse bone marrow-derived macrophages (BMDMs) 11 mM 24 h Inhibited LPS-induced Il1b gene expression and IL-1β secretion PMC7733482
bone marrow-derived monocytes 0 mM, 1 mM, 10 mM, 50 mM 4 h To assess the effect of D-mannose on macrophage phagocytic capability. It was found that as D-mannose concentration increased, the phagocytic capability of M1 and M2 macrophages significantly decreased. PMC8673064
Lymphoma YAC-1 cells 50 mM 4 h All tested sugars (including D-mannose) blocked NK cell-mediated cytotoxicity (CMC) against YAC-1 target cells PMC349512
Fibrosarcoma MethA cells 50 mM 24 h D-Mannose significantly blocked NC cell-mediated cytotoxicity (CMC) against MethA target cells PMC349512
HaCaT cells 5 mM 24-48 h D-Mannose inhibited AGEs generation and protected the physiological functions of keratinocytes under high glucose conditions. PMC11748336
NHEK cells 5 mM 24-48 h D-Mannose inhibited AGEs generation and protected the physiological functions of keratinocytes under high glucose conditions. PMC11748336
Primary mouse chondrocytes 25 mM 24 and 48 h To evaluate the protective effect of D-mannose on IL-1β-induced chondrocyte ferroptosis. Results showed that D-mannose significantly attenuated IL-1β-induced chondrocyte ferroptosis by inhibiting lipid peroxidation and upregulating the expression of GPX4 and SLC7A11. PMC8560605
gdT cells 50 mM 72 h To evaluate the impact of D-mannose on gdT cells, results showed that D-mannose treatment reduced the proliferation and glycolytic capabilities of gdT cells. PMC8918796
Primary mouse hepatocytes (PMHs) 5 mM 24 h To evaluate the effect of D-mannose on ethanol-induced lipid accumulation in hepatocytes. Results showed that D-mannose significantly reduced ethanol-induced elevation of intracellular TG and TC levels and confirmed reduced lipid droplet accumulation via BODIPY staining. PMC9021718

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
C57BL/6 mice Cisplatin-induced small intestine and kidney toxicity model Oral gavage 20% (w/v), 500 μL/day Once daily for 5 days To investigate the protective effect of D-Mannose on cisplatin-induced small intestine and kidney toxicity. Results showed that D-Mannose effectively protected the small intestine and kidney from cisplatin-induced damage by activating AMPK and suppressing GSDME cleavage. PMC10709431
Mice DSS-induced colitis model Oral 15% , dissolved in drinking water Continuous administration for 8 days To evaluate the effect of mannose on colitis development. Results showed that mannose significantly ameliorated DSS-induced colitis symptoms, including body weight loss, colon shortening, and histological damage. PMC9887054
Mice (Balb/c) LPS-induced endotoxemia model Intraperitoneal injection 2 g/kg Hourly, up to six times Reduced serum IL-1β levels and improved survival rate PMC7733482
Mice Experimental autoimmune encephalomyelitis (EAE) Intraperitoneal injection 450 mg/kg Once daily from the day of induction until day 19 To evaluate the effect of D-mannose on EAE symptoms. D-mannose treatment improved EAE symptoms, reduced MPO-mediated oxidative stress, and partially blocked macrophage/microglia phagocytosis. PMC8673064
Rats Tail-suspended rat model Intragastric administration 1.1 M Once daily for 28 days Prevented bone loss and urinary tract infections under weightlessness PMC9827691
Balb/c mice STZ-induced diabetic mice model Topical application on skin 3% (w/v) Once daily for 13 days D-Mannose significantly improved skin wound healing in diabetic mice, inhibited AGEs generation, and activated the AMPK/Nrf2/HO-1 signaling pathway. PMC11748336
C57BL/6J mice ACLT-induced osteoarthritis model Oral drinking water 20%, in drinking water Administration started two weeks before surgery and continued until 4 and 8 weeks post-surgery To evaluate the effect of D-mannose on ACLT-induced osteoarthritis progression. Results showed that D-mannose significantly alleviated cartilage degeneration, reduced OARSI scores, and inhibited HIF-2α-mediated chondrocyte ferroptosis. PMC8560605
C57BL/6 mice IMQ-induced psoriasis model Oral 20% (w/v), 200mL Twice daily for one week To evaluate the impact of D-mannose on IMQ-induced psoriasis, results showed that D-mannose treatment significantly alleviated skin inflammation. PMC8918796
C57BL/6 mice Chronic-binge ethanol feeding ALD mouse model Drinking-water supplementation 1%, 2%, 3% (w/v) 11 days To evaluate the effect of D-mannose on hepatic steatosis in ALD mice. Results showed that D-mannose significantly alleviated ethanol-induced hepatic steatosis, reduced serum ALT and AST levels, decreased hepatic TG and TC contents, and confirmed reduced hepatic lipid deposition via H&E and Oil Red O staining. PMC9021718

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT02180906 - Completed - Denmark ... More >> Copenhagen University Hospital, Rigshospitalet Copenhagen, Denmark, 2100 Less <<
NCT03267407 - Active, not recruiting March 31, 2018 Vietnam ... More >> National Hospital for Tropical Diseases Hanoi, Vietnam, 100000 Less <<
NCT00717730 Diarrhea Pneu... More >>monia Less << Phase 2 Completed - India ... More >> Society for Essential Health Action and Training New Delhi, Delhi, India Less <<
NCT01833312 Acute Ischemic Stroke Phase 3 Recruiting December 2020 Germany ... More >> Department of Neurology, University Hospital Erlangen Recruiting Erlangen, Germany, 91054 Contact: Dimitre Staykov, PD Dr.    +4991318533001    dimitre.staykov@uk-erlangen.de Less <<
NCT02998879 Alpha-Mannosidosis Phase 2 Recruiting February 2020 Austria ... More >> Recruiting Wien, Austria Denmark Recruiting Copenhagen, Denmark France Recruiting Lyon, France Germany Not yet recruiting Hamburg, Germany Recruiting Mainz, Germany Italy Not yet recruiting Trieste, Italy Less <<
NCT02865434 Arthritis, Rheumatoid Phase 1 Phase 2 Active, not recruiting December 2018 United States, Ohio ... More >> Kettering Medical Center Kettering, Ohio, United States, 45429 Less <<
NCT02997462 - Active, not recruiting December 2019 United States, Michigan ... More >> University of Michigan Health System Ann Arbor, Michigan, United States, 48109 Less <<
NCT03236272 - Recruiting December 31, 2020 China ... More >> Emergency Department, Xinqiao Hospital, Third Military Medical University Recruiting Chongqing, China Contact: HU MINGDONG, MD Less <<
NCT02478840 Alpha-Mannosidosis Phase 3 Completed - Denmark ... More >> Center for Metabolic Diseases, Department of Clinical Genetics, Juliane Marie Centre, Copenhagen University Hospital, Blegdamsvej 9 Copenhagen, Denmark, DK-2100 Less <<
NCT00674271 - Unknown May 2018 Denmark ... More >> Medical Department M, Aarhus University Hospital Aarhus C, Denmark, 8000 Less <<
NCT03436134 Kidney Transplantation ... More >> Antibody Mediated Rejection Less << Not Applicable Not yet recruiting March 1, 2021 France ... More >> Grenoble Alpes University Hospital Not yet recruiting La Tronche, France, 38700 Contact: Lionel Rosating, PHD    0476767022 ext 0033    lrostaing@chu-grenoble.fr    Contact: Paolo Malvezzi, MD    0476767022 ext 0033    Pmalvezzi@chu-grenoble.fr    Principal Investigator: lionel Rostaing, PHD          Sub-Investigator: Paolo Malvezzi, MD Less <<
NCT02332616 Osteoarthrosis Phase 3 Completed - Denmark ... More >> Bispebjerg Hospital Copenhagen NV, Denmark, 2400 Less <<
NCT01349738 - Unknown May 2013 United States, California ... More >> Scripps Green Hospital La Jolla, California, United States, 92037 Less <<
NCT02402803 - Recruiting October 2019 United States, California ... More >> Cedars Sinai Medical Center Recruiting Los Angeles, California, United States, 90048 Contact: Ying Mou, PhD    310-248-7669    ying.mou@cshs.org    Contact: Sophie Yoo, MS    424-315-4306    Jihye.Yoo@cshs.org    Principal Investigator: C. Noel Bairey Merz, MD Less <<
NCT00984516 Cicatrix Woun... More >>d-healing Less << Phase 2 Completed - United Kingdom ... More >> Renovo Manchester, United Kingdom, M13 9XX Less <<
NCT03332940 Nonalcoholic Steatohepatitis ... More >> NASH - Nonalcoholic Steatohepatitis Less << Phase 1 Active, not recruiting December 2018 United States, Ohio ... More >> Kettering Medical Center Kettering, Ohio, United States, 45429 Less <<
NCT01906229 - Terminated(Slow enrollment and... More >> therefore not possible to reach the estimated enrollment) Less << - Denmark ... More >> Intensive Care Unit, 4131, Rigshospitalet Copenhagen Ø, Denmark, 2100 Less <<
NCT00688389 - Recruiting December 31, 2020 Taiwan ... More >> Kaoshing Medical University Chung-Ho Memorial Hospital Recruiting Kaohsiung, Taiwan Contact: Jih-Jin Tsai, MD    886-7-312-1101 ext 5677    jijits@cc.kmu.edu.tw Less <<
NCT00957736 - Terminated(study closed premat... More >>urely upon PI's departure from VICC) Less << - United States, Tennessee ... More >> Vanderbilt-Ingram Cancer Center - Cool Springs Nashville, Tennessee, United States, 37064 Vanderbilt-Ingram Cancer Center at Franklin Nashville, Tennessee, United States, 37064 Vanderbilt-Ingram Cancer Center Nashville, Tennessee, United States, 37232-6838 Less <<
NCT03157167 Kaposi Sarcoma ... More >> HIV Infections Less << Phase 1 Recruiting March 2019 United States, California ... More >> Zuckerberg San Francisco General Hospital Recruiting San Francisco, California, United States, 94143 Contact: Toby A Maurer, MD       maurert@derm.ucsf.edu    Principal Investigator: Toby A Maurer, MD Less <<
NCT00006134 - Completed - United States, Alabama ... More >> University of Alabama Comprehensive Cancer Center Birmingham, Alabama, United States, 35294 United States, Texas University of Texas Medical Branch Galveston, Texas, United States, 77555-0209 University of Texas Health Science Center - Houston Houston, Texas, United States, 77225 Less <<
NCT00001702 - Completed - United States, Alabama ... More >> University of Alabama Birmingham, Alabama, United States United States, Maryland National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda, Maryland, United States, 20892 Less <<
NCT01359384 - Unknown May 2012 Germany ... More >> Children's Hospital, Goethe-University Not yet recruiting Frankfurt a. Main, Hessen, Germany, 60590 Contact: Martin Rosewich, MD       Martin.Rosewich@kgu.de Less <<
NCT00001701 - Completed - United States, Alabama ... More >> University of Alabama Birmingham, Alabama, United States Less <<
NCT03597152 Recurrent Urinary Tract Infect... More >>ion Less << Not Applicable Not yet recruiting December 31, 2020 -
NCT01889693 - Completed - Korea, Republic of ... More >> Korea University Guro Hospital Seoul, Korea, Republic of, 152-703 Less <<
NCT01275066 - Completed - -
NCT01680575 - Recruiting May 2018 Korea, Republic of ... More >> Department of Obstetrics and Gynecology, University of Ulsan College of Medicine, Asan Medical Center Recruiting Seoul, Korea, Republic of, 138-736 Contact: Jeong-Yeol Park, M.D., Ph.D. Less <<
NCT01275066 MPS IV A Phase 3 Completed - -
NCT00197847 - Unknown - Denmark ... More >> Department of Intensive Care Copenhagen, Copenhagen Couty, Denmark, DK-2730 Less <<
NCT01893489 Atherosclerosis ... More >> Carotid Atherosclerosis Noninvasive Imaging of Atherosclerosis Less << Phase 1 Completed - Korea, Republic of ... More >> Department of Nuclear Medicine, Institute of Radiation Medicine, Seoul, Korea, Republic of, 110-744 Korea University Guro Hospital Seoul, Korea, Republic of, 152-703 Less <<
NCT02894931 Dietary Habits ... More >> Serum; Disease Macrophage Atherogenicity Atherosclerosis Less << Not Applicable Unknown August 2018 Israel ... More >> Rambam Health care center Recruiting Haifa, Israel, 320000 Contact: Niroz Abu-Saleh, PhD    972504278858    asniroz@gmail.com Less <<
NCT03641690 - Completed - -
NCT02931513 - Recruiting June 2021 Denmark ... More >> Department of Hepatology and Gastroenterology, Aarhus University Hospital, Denmark Recruiting Aarhus C, Region Midtjylland, Denmark, 8000 Contact: Lars Bossen, PhD-student    +45 2280 0676    larsbossen@clin.au.dk Less <<
NCT02924701 - Recruiting June 2021 Denmark ... More >> Department of Hepatology and Gastroenterology, Aarhus University Hospital, Denmark Recruiting Aarhus C, Region Midtjylland, Denmark, 8000 Contact: Lars Bossen, PhD-student    +45 2280 0676    larsbossen@clin.au.dk Less <<
NCT02635321 - Completed - Denmark ... More >> Copenhagen Neuromuscular Center Copenhagen, Denmark, 2100 Less <<
NCT03077711 Urinary Tract Infections, Recu... More >>rrent Less << Phase 4 Active, not recruiting June 2019 United States, Illinois ... More >> NorthShore Univeristy HealthSystem Skokie, Illinois, United States, 60076 Less <<
NCT00001648 - Completed - United States, Maryland ... More >> National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda, Maryland, United States, 20892 Less <<
NCT01919931 - Completed - Belgium ... More >> Universitair Ziekenhuis Leuven Leuven, Flemish Brabant, Belgium, 3000 Less <<
NCT00648102 Breast Cancer ... More >> Colorectal Cancer Pancreatic Cancer Bladder Cancer Ovarian Cancer Less << Phase 1 Completed - United States, Michigan ... More >> Henry Ford Health System Detroit, Michigan, United States, 48202 United States, North Carolina Duke University Durham, North Carolina, United States, 27710 Carolina BioOncology Institute Huntersville, North Carolina, United States, 28078 Less <<
NCT00388999 Multiple Myeloma Phase 1 Completed - United States, Arkansas ... More >> University of Arkansas for Medical Sciences Little Rock, Arkansas, United States, 72205 Less <<
NCT00709462 Breast Cancer ... More >> Colorectal Cancer Pancreatic Cancer Bladder Cancer Ovarian Cancer Less << Phase 1 Completed - United States, Michigan ... More >> Henry Ford Health System Detroit, Michigan, United States, 48202 United States, North Carolina Duke University Durham, North Carolina, United States, 27710 Carolina BioOncology Institute Cancer Huntersville, North Carolina, United States, 28078 Less <<
NCT02702765 Wilsons Disease Not Applicable Recruiting February 2020 Denmark ... More >> Department of Hepatology and Gastroenterology, Aarhus University Hospital Recruiting Aarhus, Denmark, 8000 Contact: Jessica Björklund, Research-year student    004560748993    jebjoe@rm.dk Less <<
NCT00415311 Liver Transplantation Phase 1 Terminated(Sponsor decision to... More >> terminate the study) Less << - United States, California ... More >> University of California San Francisco San Francisco, California, United States, 94143 United States, Nebraska Nebraska Medical Center Omaha, Nebraska, United States, 68198-7400 United States, New York Mount Sinai School of Medicine New York, New York, United States, 10029 United States, Tennessee Vanderbilt University Nashville, Tennessee, United States, 372321 Less <<
NCT00520325 Cancer Hemato... More >>logic Diseases Fever Neutropenia Less << Phase 1 Withdrawn(Sponsor decision to ... More >>terminate the study) Less << - -
NCT00664352 Wound Phase 1 Phase 2 Completed - United Kingdom ... More >> 09Clinical Trials Unit, Renovo Limited Manchester, United Kingdom, M13 9XX Less <<
NCT03457038 Septic Shock Not Applicable Recruiting January 2019 France ... More >> University Hospital Toulouse Recruiting Toulouse, France, 31059 Contact: Eric Oswald, MD    5 67 69 04 17 ext 33    oswald.e@chu-toulouse.fr    Contact: Isabelle Olivier, PhD    5 61 77 70 51 ext 33    olivier.i@chu-toulouse.fr Less <<
NCT00000886 HIV Infections Phase 1 Completed - United States, New York ... More >> Univ. of Rochester AVEG Rochester, New York, United States United States, Tennessee Vanderbilt Univ. Hosp. AVEG Nashville, Tennessee, United States, 37232 United States, Washington UW - Seattle AVEG Seattle, Washington, United States, 98144 Less <<
NCT00984854 Cicatrix Re-e... More >>pithelialisation Less << Phase 1 Completed - United Kingdom ... More >> Renovo Manchester, United Kingdom, M13 9XX Less <<
NCT00854412 Obesity Weigh... More >>t Loss Less << Not Applicable Completed - -
NCT00678028 - Completed - Israel ... More >> Ha'Emek Medical Center Afula, Israel, 18101 Less <<
NCT00886496 Fever, Sweats, and Hot Flashes... More >> Infection Leukemia Lymphoma Myelodysplastic Syndromes Neutropenia Unspecified Childhood Solid Tumor, Protocol Specific Less << Phase 1 Withdrawn(No participants enro... More >>lled. IND withdrawn.) Less << - United States, California ... More >> Children's Hospital of Orange County Orange, California, United States, 92868 United States, District of Columbia Children's National Medical Center Washington, District of Columbia, United States, 20010-2970 United States, Pennsylvania Children's Hospital of Philadelphia Philadelphia, Pennsylvania, United States, 19104 Less <<
NCT03753451 Periodontal Diseases Not Applicable Completed - Brazil ... More >> INCOR- Heart Institute Sao Paulo, São Paulo, Brazil, 05403900 INCOR - Heart Institute São Paulo, Brazil, 05403-900 Less <<
NCT03395288 Urinary Tract Infections PHASE2|PHASE3 TERMINATED 2020-04-25 Washington University School o... More >>f Medicine, Saint Louis, Missouri, 63110, United States Less <<
NCT01014494 Tendon Injuries Not Applicable Unknown December 2011 United Kingdom ... More >> Mr P Gillespie Recruiting Addenbrooke's Hospital, Cambridge, Cambridge, United Kingdom, CB2 0QQ Contact: Patrick Gillespie    01223 274632    Patrick.gillespie@addenbrookes.nhs.uk    University Hospital of South Manchester NHS Foundation Trust Recruiting Manchester, Greater Manchester, United Kingdom, M23 9LT Contact: Miss V C Lees    +44 (0) 161 291 6648       Principal Investigator: Vivien C Lees          Mr F Schreuder Recruiting The Lister Hospital, Stevenage, Hertfordshire, United Kingdom Contact: Mr Schreuder    01438 781162    Fred.schreuder@nhs.net    Mr R Dunn Recruiting Salisbury District Hospital, Salisbury, United Kingdom, SP2 8BJ Contact: Roderick Dunn    01722 336262 ext 3555    sue.dubber@salisbury.nhs.uk    Mr D Warwick Recruiting Southampton General Hospital, Southampton, United Kingdom, SO16 6YD Contact: David Warwick    023 8079 5212    davidjwarwick@btinternet.com    Contact: Elaine Hayward    02380 794 989    elaine.hayward@suht.swest.nhs.uk    Royal London Hospital, Barts and The London Hospital Recruiting London, United Kingdom, E1 1BB Contact: Kamal El-Ali    07986 693062    Kamal.El-Ali@bartsandthelondon.nhs.uk    Principal Investigator: Raj Ragoowansi          Sub-Investigator: Kamal El Ali          Royal Free Hospital Recruiting London, United Kingdom, NW3 2QG Contact: Donald Dewar    020 7794 0500 ext 31302       Principal Investigator: Donald Dewar          Chelsea & Westminster Hospital Recruiting London, United Kingdom, SW10 9NH Contact: Mr Chakrabarty    020 8237 2777 ext 55490    khchakrabarty@yahoo.com    Contact: Beryl De Souza       bds@dr.com    Principal Investigator: Kaushik Chakrabarty          Sub-Investigator: Beryl De Souza          Abertawe Bro Morgannwg University Nhs Trust Recruiting Swansea, United Kingdom, SA12 7BR Contact: Mr D Boyce    +44 (0) 1792 703722       Principal Investigator: Mr D Boyce Less <<
NCT01808755 - Completed - -
NCT02823132 - Completed - France ... More >> Centre Hospitalier Universitaire Dijon, France, 21079 Less <<
NCT03497598 Urinary Tract Infections Phase 4 Recruiting June 2021 Switzerland ... More >> Kantonsspital Aarau Recruiting Aarau, Switzerland, 5001 Contact: Gloria Ryu, Dr. med Less <<
NCT01808755 Recurrent Urinary Tract Infect... More >>ion Less << Phase 3 Completed - Italy ... More >> Urology Department Fondazione IRCCS Policlinico San Matteo Pavia, Italy, 27100 Less <<
NCT02397291 IUGR Pregnanc... More >>y Less << Not Applicable Suspended June 2020 United States, Colorado ... More >> University of Colorado Denver Anschutz Medical Campus Aurora, Colorado, United States, 80045 Less <<
NCT02490046 Multiple Sclerosis ... More >> Recurrent Urinary Tract Infections Less << Phase 1 Unknown November 2015 United Kingdom ... More >> The National Hospital for Neurology and Neurosurgery Recruiting London, United Kingdom, WC1N 3BG Contact: Jalesh Panicker, MD, FRCP    020 344 84713    j.panicker@ucl.ac.uk    Contact: Véronique Phé, MD    020 344 84713    Veronique.Phe@uclh.nhs.uk    Sub-Investigator: Mahreen Pakzad, FRCS          Principal Investigator: Jalesh Panicker, MD, FRCP          Sub-Investigator: Véronique Phé, MD Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

5.55mL

1.11mL

0.56mL

27.75mL

5.55mL

2.78mL

55.51mL

11.10mL

5.55mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2
The prepared working fluid is recommended to be prepared now and used up as soon as possible in a short period of time. The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
 

Historical Records

Categories